Phase 1 Safety Study of Single and Multi-Dose Topically Applied OLT1177 Gel in Healthy Subjects

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Olatec Industries LLC
ClinicalTrials.gov Identifier:
NCT01636141
First received: July 5, 2012
Last updated: September 5, 2012
Last verified: September 2012
  Purpose

The purpose of this study is to determine if OLT1177 Gel is safe and can be tolerated when given as a single dose and multidose to a defined area of one knee of healthy subjects.


Condition Intervention Phase
Healthy Volunteers
Drug: OLT1177 Gel
Drug: Placebo gel
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 1, Randomized, Dose Escalation, Single Center, Safety Study of Single and Multi-Dose, Topically Applied OLT1177 Gel in Healthy Subjects

Further study details as provided by Olatec Industries LLC:

Primary Outcome Measures:
  • Recording of adverse events [ Time Frame: Part A - during the 7 days following the application of the study drug and Part B during the 14 day following each application of the study drug ] [ Designated as safety issue: Yes ]

    Adverse events will be described with respect to seriousness, intensity, relationship to treatment, action taken and outcome of the event.

    Local skin irritation will be assessed at each visit based on individual signs and symptoms of skin tolerability for erythema, pruritus, scaling/dryness, edema and stinging/burning.



Secondary Outcome Measures:
  • Area under the Concentration curve (AUC) [ Time Frame: Part A - Pre-dose, 15 minutes, 30 minutes, 1, 2, 4 and 6 hours post dose and Days 2, 3 and 7. Part B - Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, and 6 hours post dose, Days 2, 3 (15 minutes, 30 minutes, 1, 2, 4 and 6 hours post dose) Days 4, 7 and 14 ] [ Designated as safety issue: Yes ]

Enrollment: 36
Study Start Date: June 2012
Study Completion Date: August 2012
Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo gel
Each study group consists of 6 subjects randomized in a 5:1 ratio to receive OLT1177 Gel or placebo gel in both Part A and B of the study. Eighteen subjects will be enrolled in Part A and 18 in Part B. A total of 30 subjects will receive OLT1177 Gel and 6 subjects will receive placebo gel.
Drug: Placebo gel
none
Active Comparator: OLT1177 Gel
Each study group consists of 6 subjects randomized in a 5:1 ratio to receive OLT1177 Gel or placebo gel in both Part A and B of the study. Eighteen subjects will be enrolled in Part A and 18 in Part B. A total of 30 subjects will receive OLT1177 Gel and 6 subjects will receive placebo gel.
Drug: OLT1177 Gel
OLT1177 Gel - 3% or 5% administered topically to a defined area of one knee

Detailed Description:

OLT1177 Gel is being developed for the topical treatment of pain and inflammation emanating from musculoskeletal and certain skin inflammatory conditions.

This is a Phase 1 study evaluating the safety and tolerability of OLT1177 Gel in healthy subjects when given as single-dose or multi-dose applications. The study will be conducted in two parts, Part A and Part B. In Part A, approximately 18 healthy subjects in 3 dose escalating cohorts will be randomized to receive a single dose of the investigational drug (5 subjects OLT1177 Gel and 1 subject placebo gel). Upon completion of Part A, a new subject population of approximately 18 subjects in 3 dose escalating cohorts will be randomized in Part B of the study. Subjects will receive a total of 8 doses over 3 consecutive days given 6 hours apart while awake during the day and will be followed for up to 30 days for safety assessment.

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy men and women 18 to 60 years of age
  • Women of childbearing potential must have a negative urine pregnancy test within 3 days of study enrollment and must agree to use a highly effective form of contraception
  • Subjects must be in good health as determined by the Investigator based on medical history, ECG, physical examination and safety laboratory test
  • Ability to provide written informed consent prior to initiation of any study-related procedures, and ability, in the opinion of the Investigator, to comply with all the requirements of the study

Exclusion Criteria:

  • Subjects with a known hypersensitivity to the investigational drug
  • Subjects who are pregnant or lactating
  • Participation in any investigational drug or device study and receipt of any investigational drug or device within the immediate 30 days prior to the start of this study
  • Concurrent or recent use of analgesics, steroids, allergy medications, H2 blockers within 48 hours of the start of the study
  • Subjects with a prior knee injury or surgery within the last 5 years
  • Subjects with an active infection or with a fever ≥ 38°C within 3 days of the start of the study
  • Subjects with a history of, or known to be positive for, HIV, hepatitis B or C
  • Subjects with uncontrolled hypertension as defined by systolic blood pressure (SBP) > 150 mm/Hg, diastolic blood pressure (DBP) > 100 mm/Hg
  • Subjects with a wound or skin irritation or any skin condition, e.g., psoriasis in the treatment area
  • Subjects who are taking prescription medications with the exception of oral or systemic contraceptives
  • Subjects who have systemic diseases
  • Subjects who have a history of anaphylactic reactions to any systemic or topical compounds
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01636141

Locations
United States, Texas
J&S Studies, Inc
College Station, Texas, United States, 77845
Sponsors and Collaborators
Olatec Industries LLC
Investigators
Principal Investigator: Terry M Jones, MD J&S Studies
  More Information

No publications provided

Responsible Party: Olatec Industries LLC
ClinicalTrials.gov Identifier: NCT01636141     History of Changes
Other Study ID Numbers: OLT1177-01
Study First Received: July 5, 2012
Last Updated: September 5, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Olatec Industries LLC:
Safety
Tolerability
Pharmacokinetics
Dose escalation
Randomized
Healthy volunteers
Topical
OLT1177
Olatec
Pain
Inflammation

ClinicalTrials.gov processed this record on October 21, 2014